论文部分内容阅读
目的:研究5-HT_3受体拮抗药在武汉地区的应用情况和发展趋势。方法:采用世界卫生组织推荐的限定日剂量为指标的分析方法,对武汉地区33家医院2008～2010年5-HT_3受体拮抗药有关数据进行统计分析。结果:5-HT_3受体拮抗药销售金额逐年增加,托烷司琼使用频度的构成比最高,帕洛诺司琼的销售金额与使用频度增长迅速。结论:第一代5-HT_3受体拮抗药仍然是化疗呕吐治疗的一线用药,第二代5-HT_3受体拮抗药在治疗化疗呕吐领域越来越受到重视。
Objective: To investigate the application and development trend of 5-HT_3 receptor antagonist in Wuhan area. Methods: According to the recommended daily limit of dosage recommended by the World Health Organization (WHO), the data of 5-HT 3 receptor antagonist in 33 hospitals in Wuhan area from 2008 to 2010 were statistically analyzed. Results: The sales amount of 5-HT_3 receptor antagonist increased year by year, the constituent ratio of tropisetron was the highest, and the sales volume and frequency of palonosetron increased rapidly. Conclusion: The first generation of 5-HT_3 receptor antagonist is still the first-line treatment of chemotherapy vomiting, the second generation of 5-HT_3 receptor antagonist in the treatment of chemotherapy vomiting more and more attention.